If scalp injections deliver a hair loss treatment straight to the follicle, do they beat rubbing minoxidil onto the scalp the old-fashioned way? A 2024 systematic review gathered 11 studies comparing mesotherapy against 5% minoxidil and other conventional topicals for pattern hair loss. The reviewers found favourable efficacy and high patient satisfaction, but with honest caveats: in one trial patients felt an improvement that the density measurements could not fully confirm, and two publications described uncommon but real adverse effects.
Study by Aledani, Kaur, Kasapoglu and colleagues, published in Cureus (2024). Summarised by Malcolm Smith, Founder of Hairgenetix. Medically reviewed by Dr. Esther Bodde, MD, Cosmetic & Plastic Surgeon. Last updated 2 September 2026.
Quick answer
-
Mesotherapy came out favourably: across 11 included studies, the reviewers reported good statistical significance and high patient satisfaction in androgenetic alopecia.
-
The best trial result is patient-reported: in one included randomised trial, 69.2% of mesotherapy patients reported improved hair loss versus 37.5% on placebo (P=.028), while that trial's density change was not statistically significant (P=.054).
-
Safety was mostly reassuring, not spotless: most studies reported mild, self-limited local effects, but two publications documented uncommon adverse events.
-
The reviewers' bottom line: mesotherapy looks effective with a low rate of side effects, and larger controlled studies are still needed.
This article is part of our complete guide to hair mesotherapy.
Why does this review matter?
Mesotherapy means microinjecting medications or vitamins into the middle layer of the skin. For hair loss, the logic is delivery: the active is placed directly at follicle depth, increasing local bioavailability while lowering how much of the drug reaches the rest of the body. That matters because topical minoxidil, the standard of care, is effective but imperfect. One trial in the review, covering 381 women over 48 weeks, found that 5% topical minoxidil beat both placebo and 2% minoxidil, but caused more skin-related side effects such as itching, dermatitis, scaling and unwanted facial hair growth.
So Aledani and colleagues asked a practical question: does injecting the treatment work as well as applying it, and at what safety cost? Theirs sits alongside the Tang 2022 systematic review, which the Aledani team included among their 11 studies.
What did the review cover?
The authors followed PRISMA, the standard checklist for systematic reviews, and screened an initial pool of 18 articles down to 11 relevant studies: randomised controlled trials of injected and topical minoxidil, earlier systematic reviews, and case reports documenting complications. Together the studies covered efficacy, injection techniques, dosing and adverse effects of mesotherapy and minoxidil in androgenetic alopecia. The review also gathered technique detail: practitioners typically use fine 28 to 30 gauge needles around 4 mm long, with five described injection approaches varying needle depth and angle.
What did the review find?
| Question |
What the evidence showed |
| Overall efficacy |
Favourable, with good statistical significance across included studies |
| Patient satisfaction |
High across the included trials |
| Self-reported improvement (one included RCT) |
69.2% with mesotherapy vs 37.5% with placebo (P=.028) |
| Hair density (same RCT) |
Increased vs a decline on placebo, but not statistically significant (P=.054) |
| Safety |
Mostly mild local effects; 2 of 11 publications flagged uncommon adverse events |
The most concrete numbers come from a randomised placebo-controlled trial by Uzel and colleagues, included in the review. Fifty-four women with androgenetic alopecia received weekly intradermal injections for 10 weeks: 2 mL of 0.5% minoxidil solution or 2 mL of saline. On self-assessment, 69.2% of the mesotherapy group reported improved hair loss against 37.5% of the placebo group (P=.028). The objective measurement was less decisive: density decreased on placebo and increased with mesotherapy six weeks after the final injections, but the difference did not reach statistical significance (P=.054). To be clear, the 69.2% versus 37.5% result belongs to that single trial; the review did not pool its studies into one combined statistic.
None of the women in that trial developed hypertrichosis, the unwanted hair growth seen with topical minoxidil. They did experience self-limited pain, itching and burning, more pronounced in the mesotherapy group.
What about the adverse effects?
This is where the review earns its credibility, because it did not look away. Two of the 11 publications documented uncommon adverse events. A case series of 14 patients described frontal edema after scalp mesotherapy, along with burning, headaches, and in some cases subcutaneous necrosis, scalp abscesses and angioedema. A case report of two women who received dutasteride mesotherapy described injection-site infections, granulomatous reactions, fat necrosis and, paradoxically, two cases of non-scarring hair loss after the treatment itself.
The reviewers put these in context: fewer than 10 such problem cases were recorded across the literature they examined, and the routine side effect profile is mild local redness, pain and itching. But the events are real, mesotherapy remains unapproved by the US FDA, and they argue strongly for sterile technique and sensible product choices.
Limitations to keep in mind
A systematic review is only as strong as the studies inside it, and here those were a mixed bag: a handful of randomised trials alongside case reports and earlier reviews, with different drugs, doses and durations, so the data could not be pooled into a single effect size. The search was also restricted to English-language publications available free in full text, which can miss relevant evidence. And the standout trial numbers rest on patient self-assessment, meaningful but softer than a significant density count. The reviewers call for larger controlled studies, and that is the right reading: promising, coherent, not yet definitive.
What does this mean for your routine?
The delivery principle this review supports, getting actives to follicle depth instead of hoping they soak in, is the idea behind at-home mesotherapy done with proper single-use supplies, the approach our At-Home Hair Mesotherapy Kit packages with sterile, pre-dosed vials for a month of treatments. Our guide to the best at-home mesotherapy kits shows how the options differ. The evidence carries two practical warnings: keep everything sterile, since the serious complications in the review were largely injection-site infections, and judge results over months, not weeks, since even a 10-week trial sat on the edge of measurable density change. Our mesotherapy guide covers technique, frequency and aftercare step by step.
Frequently asked questions
Is mesotherapy better than minoxidil for hair loss?
This review found favourable efficacy and high patient satisfaction for mesotherapy, with the advantage of delivering the active directly to the follicle at lower systemic exposure. It stopped short of declaring a winner and called for larger controlled trials.
What did the 69.2% improvement figure actually measure?
Patient self-assessment in one randomised trial included in the review: 69.2% of women receiving weekly 0.5% minoxidil injections reported improved hair loss versus 37.5% on placebo (P=.028). It is a single-trial result, not a pooled figure for the whole review.
Did mesotherapy increase hair density?
In that same trial, density rose with mesotherapy while it declined on placebo, but the difference did not reach statistical significance (P=.054). Patients felt a difference before the measurements could firmly confirm one.
Is mesotherapy for hair loss safe?
Mostly. The typical side effects in the review were mild and self-limited: local pain, redness, itching and burning. Two of the 11 publications documented uncommon events, which is why sterile technique and quality products matter.
How was mesotherapy performed in these studies?
With fine 28 to 30 gauge needles about 4 mm long, injecting small amounts into the middle layer of the scalp skin. The trial with the clearest numbers used weekly sessions for 10 weeks.
References
1. Aledani EM, Kaur H, Kasapoglu M, et al. "Mesotherapy as a Promising Alternative to Minoxidil for Androgenetic Alopecia: A Systematic Review." Cureus, 2024. PubMed 38841017.
2. Uzel BP, Takano GH, Chartuni JC, et al. "Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo-controlled trial." Dermatologic Therapy, 2021. PubMed 33269529.
3. Tang Z, Hu Y, Wang J, et al. "Current application of mesotherapy in pattern hair loss: a systematic review." Journal of Cosmetic Dermatology, 2022. PubMed 35253335.
4. Gupta AK, Polla Ravi S, Wang T, et al. "Systematic review of mesotherapy: a novel avenue for the treatment of hair loss." The Journal of Dermatological Treatment, 2023. PubMed 37558233.
Mesotherapy vs Minoxidil: the Aledani 2024 Systematic Review
If scalp injections deliver a hair loss treatment straight to the follicle, do they beat rubbing minoxidil onto the scalp the old-fashioned way? A 2024 systematic review gathered 11 studies comparing mesotherapy against 5% minoxidil and other conventional topicals for pattern hair loss. The reviewers found favourable efficacy and high patient satisfaction, but with honest caveats: in one trial patients felt an improvement that the density measurements could not fully confirm, and two publications described uncommon but real adverse effects.
Study by Aledani, Kaur, Kasapoglu and colleagues, published in Cureus (2024). Summarised by Malcolm Smith, Founder of Hairgenetix. Medically reviewed by Dr. Esther Bodde, MD, Cosmetic & Plastic Surgeon. Last updated 2 September 2026.
This article is part of our complete guide to hair mesotherapy.
Why does this review matter?
Mesotherapy means microinjecting medications or vitamins into the middle layer of the skin. For hair loss, the logic is delivery: the active is placed directly at follicle depth, increasing local bioavailability while lowering how much of the drug reaches the rest of the body. That matters because topical minoxidil, the standard of care, is effective but imperfect. One trial in the review, covering 381 women over 48 weeks, found that 5% topical minoxidil beat both placebo and 2% minoxidil, but caused more skin-related side effects such as itching, dermatitis, scaling and unwanted facial hair growth.
So Aledani and colleagues asked a practical question: does injecting the treatment work as well as applying it, and at what safety cost? Theirs sits alongside the Tang 2022 systematic review, which the Aledani team included among their 11 studies.
What did the review cover?
The authors followed PRISMA, the standard checklist for systematic reviews, and screened an initial pool of 18 articles down to 11 relevant studies: randomised controlled trials of injected and topical minoxidil, earlier systematic reviews, and case reports documenting complications. Together the studies covered efficacy, injection techniques, dosing and adverse effects of mesotherapy and minoxidil in androgenetic alopecia. The review also gathered technique detail: practitioners typically use fine 28 to 30 gauge needles around 4 mm long, with five described injection approaches varying needle depth and angle.
What did the review find?
The most concrete numbers come from a randomised placebo-controlled trial by Uzel and colleagues, included in the review. Fifty-four women with androgenetic alopecia received weekly intradermal injections for 10 weeks: 2 mL of 0.5% minoxidil solution or 2 mL of saline. On self-assessment, 69.2% of the mesotherapy group reported improved hair loss against 37.5% of the placebo group (P=.028). The objective measurement was less decisive: density decreased on placebo and increased with mesotherapy six weeks after the final injections, but the difference did not reach statistical significance (P=.054). To be clear, the 69.2% versus 37.5% result belongs to that single trial; the review did not pool its studies into one combined statistic.
None of the women in that trial developed hypertrichosis, the unwanted hair growth seen with topical minoxidil. They did experience self-limited pain, itching and burning, more pronounced in the mesotherapy group.
What about the adverse effects?
This is where the review earns its credibility, because it did not look away. Two of the 11 publications documented uncommon adverse events. A case series of 14 patients described frontal edema after scalp mesotherapy, along with burning, headaches, and in some cases subcutaneous necrosis, scalp abscesses and angioedema. A case report of two women who received dutasteride mesotherapy described injection-site infections, granulomatous reactions, fat necrosis and, paradoxically, two cases of non-scarring hair loss after the treatment itself.
The reviewers put these in context: fewer than 10 such problem cases were recorded across the literature they examined, and the routine side effect profile is mild local redness, pain and itching. But the events are real, mesotherapy remains unapproved by the US FDA, and they argue strongly for sterile technique and sensible product choices.
Limitations to keep in mind
A systematic review is only as strong as the studies inside it, and here those were a mixed bag: a handful of randomised trials alongside case reports and earlier reviews, with different drugs, doses and durations, so the data could not be pooled into a single effect size. The search was also restricted to English-language publications available free in full text, which can miss relevant evidence. And the standout trial numbers rest on patient self-assessment, meaningful but softer than a significant density count. The reviewers call for larger controlled studies, and that is the right reading: promising, coherent, not yet definitive.
What does this mean for your routine?
The delivery principle this review supports, getting actives to follicle depth instead of hoping they soak in, is the idea behind at-home mesotherapy done with proper single-use supplies, the approach our At-Home Hair Mesotherapy Kit packages with sterile, pre-dosed vials for a month of treatments. Our guide to the best at-home mesotherapy kits shows how the options differ. The evidence carries two practical warnings: keep everything sterile, since the serious complications in the review were largely injection-site infections, and judge results over months, not weeks, since even a 10-week trial sat on the edge of measurable density change. Our mesotherapy guide covers technique, frequency and aftercare step by step.
Frequently asked questions
Is mesotherapy better than minoxidil for hair loss?
This review found favourable efficacy and high patient satisfaction for mesotherapy, with the advantage of delivering the active directly to the follicle at lower systemic exposure. It stopped short of declaring a winner and called for larger controlled trials.
What did the 69.2% improvement figure actually measure?
Patient self-assessment in one randomised trial included in the review: 69.2% of women receiving weekly 0.5% minoxidil injections reported improved hair loss versus 37.5% on placebo (P=.028). It is a single-trial result, not a pooled figure for the whole review.
Did mesotherapy increase hair density?
In that same trial, density rose with mesotherapy while it declined on placebo, but the difference did not reach statistical significance (P=.054). Patients felt a difference before the measurements could firmly confirm one.
Is mesotherapy for hair loss safe?
Mostly. The typical side effects in the review were mild and self-limited: local pain, redness, itching and burning. Two of the 11 publications documented uncommon events, which is why sterile technique and quality products matter.
How was mesotherapy performed in these studies?
With fine 28 to 30 gauge needles about 4 mm long, injecting small amounts into the middle layer of the scalp skin. The trial with the clearest numbers used weekly sessions for 10 weeks.
References
1. Aledani EM, Kaur H, Kasapoglu M, et al. "Mesotherapy as a Promising Alternative to Minoxidil for Androgenetic Alopecia: A Systematic Review." Cureus, 2024. PubMed 38841017.
2. Uzel BP, Takano GH, Chartuni JC, et al. "Intradermal injections with 0.5% minoxidil for the treatment of female androgenetic alopecia: a randomized, placebo-controlled trial." Dermatologic Therapy, 2021. PubMed 33269529.
3. Tang Z, Hu Y, Wang J, et al. "Current application of mesotherapy in pattern hair loss: a systematic review." Journal of Cosmetic Dermatology, 2022. PubMed 35253335.
4. Gupta AK, Polla Ravi S, Wang T, et al. "Systematic review of mesotherapy: a novel avenue for the treatment of hair loss." The Journal of Dermatological Treatment, 2023. PubMed 37558233.